Exelixis, Inc. (NASDAQ:EXEL) shares reached a new 52-week high on Monday . The company traded as high as $28.09 and last traded at $28.07, with a volume of 1,963,827 shares trading hands. The stock had previously closed at $27.23.
EXEL has been the topic of a number of research analyst reports. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Friday, June 16th. Oppenheimer Holdings, Inc. initiated coverage on shares of Exelixis in a research note on Monday, June 12th. They issued a “hold” rating on the stock. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $29.00 target price on the stock in a research note on Tuesday, July 11th. Cann restated a “hold” rating on shares of Exelixis in a research note on Thursday, July 20th. Finally, BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Exelixis currently has a consensus rating of “Buy” and an average price target of $25.57.
The firm has a market cap of $7.74 billion, a P/E ratio of 132.98 and a beta of 1.89. The company’s 50 day moving average price is $26.48 and its 200 day moving average price is $22.58.
Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $99.01 million during the quarter, compared to analyst estimates of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm’s quarterly revenue was up 173.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.15) earnings per share. On average, equities analysts predict that Exelixis, Inc. will post $0.26 earnings per share for the current fiscal year.
In related news, insider Patrick J. Haley sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.10% of the company’s stock.
A number of hedge funds have recently made changes to their positions in EXEL. Public Employees Retirement System of Ohio raised its stake in shares of Exelixis by 123.7% in the second quarter. Public Employees Retirement System of Ohio now owns 233,322 shares of the biotechnology company’s stock valued at $5,747,000 after buying an additional 129,008 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Exelixis during the second quarter valued at about $473,000. California State Teachers Retirement System raised its stake in shares of Exelixis by 14.9% in the second quarter. California State Teachers Retirement System now owns 515,076 shares of the biotechnology company’s stock valued at $12,686,000 after buying an additional 66,783 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Exelixis by 1,923.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 263,086 shares of the biotechnology company’s stock valued at $6,480,000 after buying an additional 250,086 shares in the last quarter. Finally, Caxton Associates LP purchased a new position in shares of Exelixis during the second quarter valued at $227,000. Institutional investors own 79.93% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Exelixis, Inc. (EXEL) Reaches New 1-Year High at $28.09” was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/exelixis-inc-exel-sets-new-1-year-high-at-28-09-updated-updated-updated.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.